Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 12/20 | 0.41 |
| ▸ | CA1 | P00915 | 12/20 | 0.41 |
| ▸ | CA2 | P00918 | 12/20 | 0.41 |
| ▸ | CA4 | P22748 | 12/20 | 0.41 |
| ▸ | CA7 | P43166 | 12/20 | 0.41 |
| ▸ | CA9 | Q16790 | 12/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809300 | 1.00 | CA12 (0.41) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2804851 | 0.96 | CA12 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2804846 | 0.96 | CA12 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2805239 | 0.94 | CA12 (0.39) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2805244 | 0.94 | CA12 (0.39) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2805073 | 0.93 | CA12 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2805066 | 0.93 | CA12 (0.44) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2806411 | 0.91 | CA12 (0.41) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2806410 | 0.91 | CA12 (0.41) | CA12CA1CA2CA4CA7 | |
| SCHEMBL2809148 | 0.90 | CA12 (0.42) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044070-B1 | PURINE DERIVATIVES AS A2A AGONISTS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | claimed |
| US-8071565-B2 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2011-12-06 | — | — | US | disclosed |
| US-20100240680-A1 | Purine derivatives as a2a agonists | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| EP-1889846-A1 | Purine derivatives as A2a agonists | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240680-A1 | Purine derivatives as a2a agonists | ADORA2A, ADORA1, ADORA3 | CA12 4759/4885CA1 4404/4885CA2 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.